These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26775630)

  • 21. [Meta-analysis on the stroke with overweight or obesity, smoking and alcohol drinking in Chinese residents].
    Wang J; Ye DQ; Wang K
    Zhonghua Yu Fang Yi Xue Za Zhi; 2008 Feb; 42(2):115-8. PubMed ID: 18642665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index.
    Wang Z; Xu M; Hu Z; Shrestha UK
    Menopause; 2015 Jun; 22(6):667-73. PubMed ID: 25513983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease.
    Boyle M; Masson S; Anstee QM
    J Hepatol; 2018 Feb; 68(2):251-267. PubMed ID: 29113910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations.
    Almeda-Valdes P; Aguilar-Salinas CA; Uribe M; Canizales-Quinteros S; Méndez-Sánchez N
    Eur J Clin Invest; 2016 Nov; 46(11):940-946. PubMed ID: 27600089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic.
    Doycheva I; Watt KD; Alkhouri N
    Hepatology; 2017 Jun; 65(6):2100-2109. PubMed ID: 28103626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk stratification of adolescents for the screening of non-alcoholic fatty liver disease.
    Abrams GA; Ware D; Byrne MM; Hecht EM
    Pediatr Obes; 2022 Sep; 17(9):e12924. PubMed ID: 35501286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations in the search for under-reported alcohol consumption in NAFLD.
    Hagström H; Ekstedt M
    J Hepatol; 2023 Feb; 78(2):e66-e67. PubMed ID: 35863490
    [No Abstract]   [Full Text] [Related]  

  • 28. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
    Gastaldelli A
    Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alcohol consumption, weight gain, and risk of becoming overweight in middle-aged and older women.
    Wang L; Lee IM; Manson JE; Buring JE; Sesso HD
    Arch Intern Med; 2010 Mar; 170(5):453-61. PubMed ID: 20212182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
    Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
    World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall HU; Hultcrantz R; Stål P
    Scand J Gastroenterol; 2017 Feb; 52(2):159-165. PubMed ID: 27650916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnosis and treatment strategies for fatty liver when obesity coexists with alcohol consumption].
    Sun FR; Wang BY
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):212-216. PubMed ID: 32306654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of cardiovascular risk factors among workers at a private tertiary center in Angola.
    Paquissi FC; Manuel V; Manuel A; Mateus GL; David B; Béu G; Castela A
    Vasc Health Risk Manag; 2016; 12():497-503. PubMed ID: 28008265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does vitamin C deficiency promote fatty liver disease development?
    Ipsen DH; Tveden-Nyborg P; Lykkesfeldt J
    Nutrients; 2014 Dec; 6(12):5473-99. PubMed ID: 25533004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NAFLD prevalence and severity in overweight and obese populations.
    Francque SMA; Dirinck E
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):2-3. PubMed ID: 36400096
    [No Abstract]   [Full Text] [Related]  

  • 36. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.
    Abenavoli L; Milic N; Peta V; Alfieri F; De Lorenzo A; Bellentani S
    World J Gastroenterol; 2014 Dec; 20(45):16831-40. PubMed ID: 25492997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011).
    Lee YH; Jung KS; Kim SU; Yoon HJ; Yun YJ; Lee BW; Kang ES; Han KH; Lee HC; Cha BS
    J Hepatol; 2015 Aug; 63(2):486-93. PubMed ID: 25772036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals.
    Fukuda T; Hamaguchi M; Kojima T; Hashimoto Y; Ohbora A; Kato T; Nakamura N; Fukui M
    Liver Int; 2016 Feb; 36(2):275-83. PubMed ID: 26176710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk.
    Oni ET; Kalathiya R; Aneni EC; Martin SS; Blaha MJ; Feldman T; Agatston AS; Blumenthal RS; Conceiçao RD; Carvalho JA; Santos RD; Nasir K
    Am J Cardiol; 2015 Jan; 115(1):34-9. PubMed ID: 25456868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.